Roth Keeps Spectrum Pharma (SPPI) at Buy; Q4 Results are Speed Bump on Road to Profitability
Tweet Send to a Friend
Roth Capital maitnains its Buy rating and $15 price target on Spectrum Pharma (Nasdaq: SPPI) following Q4 results issued Thursday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
